502 related articles for article (PubMed ID: 27039171)
1. Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives.
Moehler M; Delic M; Goepfert K; Aust D; Grabsch HI; Halama N; Heinrich B; Julie C; Lordick F; Lutz MP; Mauer M; Alsina Maqueda M; Schild H; Schimanski CC; Wagner AD; Roth A; Ducreux M
Eur J Cancer; 2016 May; 59():160-170. PubMed ID: 27039171
[TBL] [Abstract][Full Text] [Related]
2. [Advances in immune checkpoint inhibitors in gastrointestinal cancer].
Zhu XR; Zheng LZ
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):646-649. PubMed ID: 28926891
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors in the Treatment of Gastrointestinal Malignancies: A Review of Current and Future Therapies.
Hsu A; Mendelson L; Almhanna K
R I Med J (2013); 2020 Apr; 103(3):33-37. PubMed ID: 32236159
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
[TBL] [Abstract][Full Text] [Related]
5. Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.
Solomon BL; Garrido-Laguna I
Future Oncol; 2018 Apr; 14(10):947-962. PubMed ID: 29542354
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
8. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
9. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
Lote H; Cafferkey C; Chau I
Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
[TBL] [Abstract][Full Text] [Related]
10. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for immune therapy in gastrointestinal cancers.
Weinberg BA; Hameed R; Marshall JL
Clin Adv Hematol Oncol; 2019 Feb; 17(2):109-119. PubMed ID: 30845114
[TBL] [Abstract][Full Text] [Related]
14. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy beyond immune checkpoint inhibitors.
Marin-Acevedo JA; Soyano AE; Dholaria B; Knutson KL; Lou Y
J Hematol Oncol; 2018 Jan; 11(1):8. PubMed ID: 29329556
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives.
Abdul-Latif M; Townsend K; Dearman C; Shiu KK; Khan K
Cancer Treat Rev; 2020 Aug; 88():102030. PubMed ID: 32505807
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
Lazăr DC; Avram MF; Romoșan I; Cornianu M; Tăban S; Goldiș A
World J Gastroenterol; 2018 Aug; 24(32):3583-3616. PubMed ID: 30166856
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
19. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
[TBL] [Abstract][Full Text] [Related]
20. Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets.
Kumar AR; Devan AR; Nair B; Vinod BS; Nath LR
Mol Biol Rep; 2021 Dec; 48(12):8075-8095. PubMed ID: 34671902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
